ACCESS Newswire
21 May 2020, 17:01 GMT+10
SEATTLE, WA / ACCESSWIRE / May 21, 2020 / OncoResponse Inc., a biotechnology company developing human antibodies as product candidates for multiple high value targets associated with immunosuppressive myeloid biology for application to cancer immunotherapy, today announced that Clifford Stocks, Chief Executive Officer, plans to present an overview of the company and discuss the Series C financing at the upcoming Solebury Trout Virtual Global Healthcare Conference. During the 25-minute presentation, participants will be able to submit questions electronically with answers provided at the discretion of the company on an individual basis afterwards. Details are as follows:
Date/Time: Tuesday, May 26, 2020 at 1:30 PM EDT
To access the presentation, please login
HERE: https://78449.themediaframe.com/dataconf/productusers/solebury/mediaframe/38244/indexl.html
Webcast archive: 24 hours following the presentation an archive of the event will be available on the Company's website at: http://www.oncoresponseinc.com/
ABOUT ONCORESPONSE
OncoResponse, Inc., an immuno-oncology focused biotech company, in a broad strategic alliance with MD Anderson Cancer Center uses a proprietary B-cell technology platform to mine the immune system of cancer patients who have responded to cancer immunotherapy to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies to treat cancer. OncoResponse has several antibodies directed at modulating immunosuppression of the tumor microenvironment in pre-clinical development. OncoResponse, Inc. is a privately held company backed by investment from MD Anderson Cancer Center, Rivervest Venture Partners, Qatar Investment Authority, Redmile Group, ARCH Venture Partners, GreatPoint Ventures, Helsinn Investment Fund, Canaan Partners, Shire, Buchang Pharma (China), Alexandria Real Estate Equities and William Marsh Rice University. For more information please visit: www.oncoresponseinc.com
INVESTOR CONTACTS
John Graziano
Solebury Trout
+1 646-378-2942
[email protected]
SOURCE: OncoResponse, Inc. via EQS Newswire
Get a daily dose of Los Angeles Herald news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Los Angeles Herald.
More InformationMOSCOW, Russia: This week, Russia became the first country to officially recognize the Taliban as the government of Afghanistan since...
CAIRO, Egypt: This week, both Hamas and Israel shared their views ahead of expected peace talks about a new U.S.-backed ceasefire plan....
WASHINGTON, D.C.: The Trump administration has made public a visa decision that would usually be kept private. It did this to send...
MADRID, Spain: Liverpool footballer Diogo Jota and his younger brother, André Silva, have died in a car accident in Spain. Spanish...
LONDON, U.K.: An unrelenting heatwave sweeping across Europe has pushed early summer temperatures to historic highs, triggering deadly...
President Donald Trump's plans to build a space-based Golden Dome missile defense shield have drawn immediate criticism from China,...
PALO ALTO/TEL AVIV: The battle for top AI talent has claimed another high-profile casualty—this time at Safe Superintelligence (SSI),...
SANTA CLARA, California: Nvidia came within a whisker of making financial history on July 3, briefly surpassing Apple's all-time market...
SACRAMENTO, California: California's multibillion-dollar farms are facing a growing crisis—not from drought or pests, but from a sudden...
SAN FRANCISCO, California: Grammarly is doubling down on AI-powered productivity tools with the acquisition of Superhuman, a sleek...
MENLO PARK, California: Robinhood is giving European investors a new way to tap into America's most prominent tech names — without...
WASHINGTON, DC - U.S. President Donald Trump on Tuesday claimed Elon Musk's success has been built on government subsidies. Without...